TEAM JOOST SCHANSTRA

CHRONIC KIDNEY DISEASE

Chronic kidney disease has remained a rather “silent” epidemic but recent data have shown that its prevalence has now exceeded 10% of the general population with wide socioeconomic-impact. Our team therefore focusses on early detection, understanding and discovery of molecules that potentially will be able to slow down kidney disease progression and its cardiovascular complications.

TEAM

 
Tous / AllTeam leaderResearchersCliniciansTechnical staffStudents
Team Leader

Joost SCHANSTRA

Assistant Professor

Bénédicte BUFFIN-MEYER

Principal Scientist

Julie KLEIN

Assistant Professor

Colette DENIS

Principal Scientist

Jean-Sebastien SAULNIER-BLACHE

Clinician

Julie BELLIERE

Clinician

Dominique CHAUVEAU

Clinician

Stéphane DECRAMER

Clinician

Stanislas FAGUER

Clinician

Ivan TACK

Engineer

Benjamin BREUIL

Engineer

Mélinda ALVES

Engineer

Marie BULEON

Engineer

Audrey CASEMAYOU

Engineer

Guylène FEUILLET

Engineer

Eric NEAU

PhD Student

Ana AMAYA GARRIDO

PhD Student

Lucile GRZESIAK

PhD Student

Alexis PIEDRAFITA

PhD Student

Snigdha RAO

Student

Sofiane SALHI

Scientific mediation

François CHAMARAUX

Team Leader

Joost SCHANSTRA

PhD, Director of research, Group leader

Career path

Joost Schanstra received his PhD in Biochemistry from the University of Groningen in the Netherlands in 1996. From 1996 to 1999 he worked as a post-doctoral fellow in the field of Nephrology and was re-cruited as a principal investigator at INSERM, Toulouse, in 1999. Since 2008, Joost Schanstra is a Director of research at the Renal Fibrosis Lab, INSERM U1297.

Main domains of expertise:
Clinical proteomics, Chronic kidney disease, Systems biology, Urinary biomarkers

Assistant Professor

Bénédicte BUFFIN-MEYER

Bénédicte Buffin-Meyer: PhD, HDR, Associate professor University Paul Sabatier, Principal investigator

Career path

Bénédicte Buffin-Meyer received her PhD in 1996 from the University of Paris-Sud/Orsay. Her thesis aimed to improve the understanding of renal adaptation mechanisms. Then she completed a 3-year post-doctoral fellowship in the field of biochemistry. In 1999, she was recruited as Associate Professor in Physiology at the Paul Sabatier University, and until 2007, she was interested in the pharmacology of epithelial cells, especially in the kidney. Since 2007, she performs her research at the laboratory of renal fibrosis, INSERM U1297.

Main domains of expertise:

Renal cellular biology, Urinary shear stress, Kidney disease, Clinical peptidomics, Metabolomics,

Principal Scientist

Julie KLEIN

Julie Klein, PhD, Researcher Inserm, Principal investigator

Career path

Julie Klein received her PhD from the University Paul Sabatier, Toulouse, France, in 2009. From 2009 to 2014 she worked as a post-doctoral fellow in the field of proteomics and bioinformatics in chronic kidney disease and was recruited as a researcher at the Renal Fibrosis Lab, INSERM U1048, Toulouse in 2014.

Main domains of expertise

Bioinformatics tools and databases (KUPKB, Proteasix, PRYNT), Clinical proteomics, Cardiovascular complications of chronic kidney disease, Mechanisms of chronic kidney disease, Urinary biomarkers

 

Assistant Professor

Colette DENIS

Colette Denis, PhD, HDR, Associate professor University Paul Sabatier, Principal investigator

Career path

Colette Denis received her PhD from the University Paul Sabatier, Toulouse, France, in 1985 and was recruited as an Associate Professor at University Paul Sabatier in 1988. From 1983 to 1990 she worked on the regulation of glycolysis in intestinal adenocarcinoma cells, and from 1990 to 2014 she specialized in molecular pharmacology. Since 2015, Colette Denis is a principal investigator at the Renal Fibrosis Lab, INSERM U11297.

Main domains of expertise

Pharmacology, Kidney physiology, Plasma /urine biochemistry, Histology, pesticides and kidney.

Principal Scientist

Jean-Sebastien SAULNIER-BLACHE

Jean Sébastien Saulnier-Blache (PhD, Research Director).

Career path

Jean Sébastien Saulnier-Blache obtained his PhD in Molecular Pharmacology from the Paul Sabatier University in Toulouse in 1990, and obtained a principal investigator position at INSERM in Toulouse. After 2 years as a post-doctoral fellow in the Molecular Biology field at the University of South Carolina (Charleston, SC), he continued his career at INSERM in Toulouse.

Main domains of expertise

pathophysiology of obesity and diabetes, adipose tissue development and metabolism, phospholipid mediators, chronic kidney disease.

Email:jean-sebastien.saulnier-blache@inserm.fr

Tél/Phone:0531224076 

Clinician

Julie BELLIERE

Clinician

Dominique CHAUVEAU

Clinician

Stéphane DECRAMER

Clinician

Stanislas FAGUER

Stanislas Faguer, MD, PhD, Professor of Nephrology

Career path

Stanislas Faguer received his PhD in Molecular Genetic at the University Hospital of Toulouse in 2013, and his MD in 2010. He also received additional graduations in Nephrology (2011), Critical care medicine (2015) and clinical Immunology (2015). He was Associated Professor in the Department of Nephrology and Organ Trnasplantation at the University Hospital of Toulouse from 2015 to 2018, and is now Professor in this Department. He is also involved in the reference center for rare kidney diseases (SORARE) in Toulouse.

Main domains of expertise

Acute kidney injury, transcription factors, kidney tubules, rare immunological disorders.

Clinician

Ivan TACK

Engineer

Benjamin BREUIL

Benjamin Breuil, Engineer Inserm

Career path

Benjamin Breuil received his technical degree in France, in 1998. From 1999 to 2008 he worked as an assistant engineer in food security and pharmaceutical companies and acquired different skills in analytical chemistry, robotic and transcriptomics. Recruited permanently at INSERM in 2014, promoted engineer in 2020, Benjamin Breuil is a member of the Renal Fibrosis Lab, INSERM U1297 since 2008.

Main domains of expertise

Urinary biomarker, Clinical proteomics, Metabolomics, Capillary Electrophoresis coupled to Mass Spectrometry (CE-MS)

Engineer

Mélinda ALVES

Melinda Alves, Engineer Inserm

Career path

Melinda Alves received her Master degree in Health Biology option Virology, Gene Therapy and Vectorology from the Paul Sabatier University, Toulouse, France, in 2019. She joined the Renal Fibrosis Lab, in September 2019 as an engineer in the field of renal failure at INSERM U1297.

Main domains of expertise

Animal experiments, Acute kidney disease, Histology, Cellular & Molecular Biology

Engineer

Marie BULEON

Marie Buléon, Engineer University Paul Sabatier

Career path

Marie Buléon received her PhD from the University Paul Sabatier, Toulouse, France, in 2008. From 2004 to 2008 she worked as a PhD student in chronic kidney disease. She was recruited as an Engineer at the Renal Fibrosis Lab, INSERM U1297, in 2009.

Main domains of expertise

Animal experiments, Histology, Plasma/urine biochemistry, Acute kidney disease, Chronic kidney disease,

Engineer

Audrey CASEMAYOU

Audrey Casemayou, Engineer, CHU Toulouse

Career path

Audrey Casemayou received her PhD from the University Paul Sabatier, Toulouse, France, in 2010 in the field of regulatory T cells and experimental autoimmune encephalomyelitis. From 2011 to  2019 she worked as a post-doctoral researcher in the field of HNF1B and acute renal diseases at the Renal Fibrosis Lab, INSERM U1048. Since 2019, she was recruited as an engineer at the Renal Fibrosis Lab.

Main domains of expertise

Acute kidney disease, HNF1beta, Cellular & Molecular biology, Histology/immunohistochemistry, Renal fibrosis mechanisms

Engineer

Guylène FEUILLET

Engineer University Paul Sabatier

Career path

Guylène Feuillet received her master degree from the University Claude Bernard, Lyon, France, in 2005. From 2005 to 2014 she worked as an engineer in the field of intestinal diseases at INRA Toxalim/INSERM CPTP, Toulouse. Since 2015, Guylène Feuillet is an engineer at the Renal Fibrosis Lab, INSERM U1048.

Main domains of expertise

Animal experiments, Histology/immunohistochemistry, Biochemistry, Molecular biology

Engineer

Eric NEAU

 Engineer Inserm

Career path

Eric Neau received his master degree in cellular biology, option genetics from the University Pierre and Marie Curie, (UPMC Paris VI), France, in 1989. From 1991 to 1999 he worked as an assistant engineer at INSERM U 142, Hôpital St Antoine (Paris) in the field of gene expression IGFBP1 (insulin-like growth factor binding protein 1) in liver and endometrium and, was recruited as an assistant engineer at INSERM, Toulouse, in 1999. Since 2008, Eric Neau is a research engineer at the Renal Fibrosis Lab, INSERM U1048.

Main domains of expertise

Molecular biology, Quantitative PCR, miRNA

PhD Student

Ana AMAYA GARRIDO

Ana Amaya Garrido, PhD Student

Ana graduated in Biochemistry and Biotechnology in University of Malaga in 2016 and obtained her master degree in biochemical sciences, in Hasselt, Belgium  in 2018. In September of 2018 she was recruited as a PhD student at the RF Lab. Her project is part of an European Marie-Curie Innovative Training Network (CaReSyAn) in the field of cardiorenal syndrome. She studies the role of identified biomarkers in chronic kidney disease patients presenting cardiovascular complications.

PhD Student

Lucile GRZESIAK

PhD Student (MNRT Grant)

During her PhD, she is working on identifying new molecules involved in the development of vascular calcification.

Career path
Bachelor in Biosciences completed at Robert Gordon University in Scotland in 2016. Master of integrative biology and physiology obtained at Sorbonne University in 2018 (speciality in human pathophysiology)

Main domain of expertise
Cellular biology, vascular calcification and histology

PhD Student

Alexis PIEDRAFITA

PhD Student

Snigdha RAO

Snigdha Rao, PhD student

Career path

Snigdha completed her Bachelor’s in Engineering (Biotechnology) from M S Ramaiah Institute of Technology, Bengaluru in 2016. Subsequently she obtained her Master’s degree in Molecular Biology from Umeå University, Sweden. She then worked at Jubilant Biosys Limited, Bengaluru in the Oncology team, after which she worked as a Junior Research Fellow at the Institute of Bioinformatics and Applied Biotechnology, Bengaluru, where her work focused on the generation of engineered cells for therapy. In December 2020, she joined the RF Lab as a PhD student in the CARe PhD program to study immunosenescence targeting to prevent kidney disease in the elderly.

Student

Sofiane SALHI

Scientific mediation

François CHAMARAUX

François Chamaraux, Scientific mediator, Inserm

Career path

After a PhD in biophysics (“Cell motility by actin polymerization: some experimental and theoretical aspects”), obtained in 2005 at the University of Lyon, François Chamaraux turned to teaching physics and mathematics on the one hand (ULB/EPFC, Brussels), and scientific mediation on the other hand (general scientific papers, workshops intended for general public, adults and children). Since 2021, he is a scientific mediator in the SoEcoHealth project, for the network Holimitox.

Email:francois.chamaraux@inserm.fr

Site:https://ligue-enseignement.be/

CAKUT: Anomalies of the kidney and the urinary tract

 

Coordinators: Bénédicte Buffin-Meyer, Stéphane Decramer, Jean-Sébastien Saulnier-Blache

Congenital anomalies of the kidney and urinary tract (CAKUT) are rare developmental diseases. Although rare, they are the first cause of end-stage kidney disease in children. We develop tools to detect at an early-stage (often in-utero) patients with a high risk of developing severe disease using body fluid omics analysis and aim to better understand the role of specific proteins in the development of CAKUT.

Acute kidney injury

 

Coordinators: Julie Bellière, Stanislas Faguer

Acute kidney injury (AKI) leads to 1.7 million deaths every year worldwide. Compared to other kidney diseases, AKI is is a highly dynamic disease based on a subtle interplay between the epithelial, vascular and immune cells recruited from the circulation in the injured kidney. We aim to study this interplay to generate multiple anchors for detection and intervention.

Cardiovascular complications in chronic kidney disease

 

Coordinator: Julie Klein

Cardiovascular complications are the major causes of mortality in patients with chronic kidney disease. This is mostly due to vascular calcification. Using body fluid omics analysis, we aim to detect at an early stage those patients at high risk of developing such complications and develop novel pharmacological interventions.

So-EcoHealth

 

Coordinator: Colette Denis

Succinate DeHydrogenase Inhibitors (SDHI), are a family of fungicides increasingly used in agriculture. As mitochondrial dysfunction is recognized as an initiator and contributor to a number of renal diseases, we investigate the impact of SDHI exposure in acute kidney injury and progression towards chronic kidney disease. This project is part of the Holimitox network.

RECENT PUBLICATIONS

Mapping of the amniotic fluid proteome of fetuses with congenital anomalies of the kidney and urinary tract identifies plastin 3 as a protein involved in glomerular integrity, Fédou C, Camus M, Lescat O, Feuillet G, Mueller I, Ross B, Buléon M, Neau E, Alves M, Goudounéche D, Breuil B, Boizard F, Bardou Q, Casemayou A, Tack I, Dreux S, Batut J, Blader P, Burlet-Schiltz O, Decramer S, Wirth B, Klein J, Saulnier-Blache JS, Buffin-Meyer B, Schanstra JP. J Pathol. 2021. Pubmed

PRYNT: a tool for prioritization of disease candidates from proteomics data using a combination of shortest-path and random walk algorithms, Boizard F, Buffin-Meyer B, Aligon J, Teste O, Schanstra JP, Klein J. Sci Rep. 2021. Pubmed

Administration of the High-Density Lipoprotein Mimetic CER-001 for Inherited Lecithin-Cholesterol Acyltransferase Deficiency, Faguer S, Chauveau D, Colombat M, Delas A, Bernadet-Monrozies P, Beq A, Soler V, Labadens I, Huart A, Benlian P, Schanstra JP. Ann Intern Med. 2021. Pubmed

Amniotic fluid peptides predict postnatal kidney survival in developmental kidney disease, Klein J, Buffin-Meyer B, Boizard F, Moussaoui N, Lescat O, Breuil B, Fedou C, Feuillet G, Casemayou A, Neau E, Hindryckx A, Decatte L, Levtchenko E, Raaijmakers A, Vayssière C, Goua V, Lucas C, Perrotin F, Cloarec S, Benachi A, Manca-Pellissier MC, Delmas HL, Bessenay L, Le Vaillant C, Allain-Launay E, Gondry J, Boudailliez B, Simon E, Prieur F, Lavocat MP, Saliou AH, De Parscau L, Bidat L, Noel C, Floch C, Bourdat-Michel G, Favre R, Weingertner AS, Oury JF, Baudouin V, Bory JP, Pietrement C, Fiorenza M, Massardier J, Kessler S, Lounis N, Auriol FC, Marcorelles P, Collardeau-Frachon S, Zürbig P, Mischak H, Magalhães P, Batut J, Blader P, Saulnier Blache JS, Bascands JL, Schaefer F, Decramer S, Schanstra JP; BIOMAN consortium. Kidney Int. 2021. Pubmed

Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment, Schanstra JP, Luong TT, Makridakis M, Van Linthout S, Lygirou V, Latosinska A, Alesutan I, Boehme B, Schelski N, Von Lewinski D, Mullen W, Nicklin S, Delles C, Feuillet G, Denis C, Lang F, Pieske B, Bascands JL, Mischak H, Saulnier-Blache JS, Voelkl J, Vlahou A, Klein J. JCI Insight 2019. Pubmed

They are supporting our research

logotype i2mc
logotype i2mc

Inserm/UPS UMR 1297 - I2MC Institut des Maladies Métaboliques et Cardiovasculaires

1 avenue Jean Poulhès - BP 84225 - 31432 Toulouse Cedex 4

Tél. : 05 61 32 56 00

Contactez-nous

 

Horaires

Du lundi au vendredi
8h30 - 12h30 / 13h45 -16h45